UBS Group AG Buys 215,645 Shares of Niagen Bioscience, Inc. $NAGE

UBS Group AG raised its stake in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) by 18.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,411,742 shares of the company’s stock after acquiring an additional 215,645 shares during the period. UBS Group AG’s holdings in Niagen Bioscience were worth $8,979,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of NAGE. Hillsdale Investment Management Inc. acquired a new position in Niagen Bioscience during the third quarter worth $2,988,000. JPMorgan Chase & Co. acquired a new position in Niagen Bioscience during the third quarter worth $3,678,000. Gamco Investors INC. ET AL acquired a new position in Niagen Bioscience during the third quarter worth $1,170,000. Navellier & Associates Inc. acquired a new position in Niagen Bioscience during the third quarter worth $1,768,000. Finally, Gabelli Funds LLC acquired a new position in Niagen Bioscience during the third quarter worth $1,749,000. 15.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. HC Wainwright lowered their price objective on shares of Niagen Bioscience from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Canaccord Genuity Group lowered their price objective on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Wall Street Zen downgraded shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

Niagen Bioscience Price Performance

Shares of NAGE stock opened at $3.65 on Monday. The firm has a 50-day moving average of $4.60 and a 200-day moving average of $5.67. The company has a market cap of $290.69 million, a P/E ratio of 17.38 and a beta of 2.17. Niagen Bioscience, Inc. has a one year low of $3.60 and a one year high of $14.69.

Niagen Bioscience (NASDAQ:NAGE) last announced its earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. The company had revenue of $31.47 million during the quarter. Niagen Bioscience had a net margin of 14.29% and a return on equity of 22.68%. As a group, research analysts expect that Niagen Bioscience, Inc. will post 0.22 earnings per share for the current fiscal year.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.